Later-line advanced gastric cancer therapy is tough. This phase II trial of FTD/TPI + ramucirumab showed feasible delivery, a 76.9% DCR, 4.0-mo median TTF, and manageable toxicity (mostly neutropenia). It offers key data on routine-care tolerability. Learn more: https://bit.ly/3R9iUYV

Who gets represented in cancer clinical trials? An analysis across 3 NCI cancer centers found enrollment gaps varied by site for minorities, rural residents, Medicaid patients, & non-English speakers. Measuring this is step 1 to equity. Read the full article: https://bit.ly/4vcUaNt

How do pediatric phase 1 trials shape targeted therapy? By balancing efficacy with long-term safety. A new study on tovorafenib established phase 2 dosing and flagged growth suppression risks for new pediatric low-grade glioma treatments. Read the full article: https://bit.ly/4eHA7lm

Vincristine neuropathy in pediatric ALL can persist past therapy. This UKALL 2011 sub-study used gait analysis to show that omitting maintenance pulses safely reduced this functional burden—a vital reminder for survivorship. Read more: https://bit.ly/4y4lujG

Over 1.3M cervical cancer deaths were avoided across 48 countries since peak mortality. This study highlights the impact of HPV vaccination, screening, and treatment, showing both progress and remaining challenges toward elimination. Read the full article: https://bit.ly/4wjxWtZ

Read on for recommendations on how to maximize research potential of limited biopsy tissue and optimize workflows to improve assay success rates and data reproducibility in large-scale oncology trials. Read the article. https://bit.ly/3QHly87

#JCO welcomes Tom Wei-Wu Chen, MD, PhD, as our newest Consultant Editor. Welcome, Dr. Chen!

JCO Oncology Practice would like to welcome our newest Associate Editor Edward S. Kim, MBA, MD, FASCO, FACP, of City of Hope in Irvine, California. #JCOOP

Can a noninvasive salivary exosome-based RNA panel detect esophageal squamous cell carcinoma (ESCC) and stratify patient prognosis across multiple centers? Read the article. https://bit.ly/4f8s4gr

Join us in honoring the 2026 JCO Oncology Practice Editorial Fellows! We’re proud to support them as they dive into peer review alongside our mentors. Learn more about editorial fellow: https://bit.ly/44hDbhL

New content alert: Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer Detection. Read the article: https://bit.ly/4euYJxv #gyncsm

Join us in honoring the 2026 2026 JCO Global Oncology Editorial Fellows! We’re proud to support these oncology fellows as they dive into peer review alongside our mentors. Thank you for your dedication! Learn more about becoming an editorial fellow: https://bit.ly/4abgNKx

Join us in honoring the 2026 JCO Oncology Advances Editorial Fellows! We’re proud to support these oncology fellows as they dive into peer review alongside our mentors. Thank you for your dedication! Learn more about becoming an editorial fellow: https://bit.ly/4vYw2Pm

New content alert: Real-World Pt Characteristics, Mutational Landscape & Outcomes in Adv./Metastatic HER2-Mutant Non-Small Cell Lung Cancer ➡️ https://bit.ly/4eEPpFX Pts w advanced or metastatic #NSCLC with HER2 mutations were diagnosed between Jan 1, 2015, & June 30, 2022. @lungoncdoc.bsky.social#NSCLC

Join us in honoring the 2026 JCO CCI Editorial Fellows! We’re proud to support these oncology fellows as they dive into peer review alongside our mentors. Learn more: https://bit.ly/4eAx2lK

Join us in honoring the 2026 JCO Precision Oncology Editorial Fellows! We’re proud to support these oncology fellows as they dive deep into peer review and medical publishing alongside our editor mentors. Learn more about becoming an editorial fellow: https://bit.ly/4a8R8lC

JCO is proud to announce our 2025 Impact Factor of 44.7 as a top-cited oncology journal! Thank you to our incredible authors and reviewers for helping us translate authoritative, peer-reviewed science into better outcomes for cancer patients worldwide. Submit: https://bit.ly/4fOcx7k

‼️ #EHA2026 simultaneous publication by @mattwilson2287 et al:  High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Analysis of 1,923 Patients Read the full article: https://bit.ly/4efwgue

#EHA2026 simultaneous publication by @ghayasissa et al:  The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE) Read the full article: https://bit.ly/4ofhU1k

‼️ #ASCO26 simultaneous publication by Mascarenhas et al: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial Read the full article: https://bit.ly/3RQ1Eb3

‼️ #ASCO26 simultaneous publication by McDonald et al: GLP-1 agonists are associated with a significant reduction in breast cancer incidence in women Read the full article: https://bit.ly/4v88xTu #bcsm

️ ‼️ #ASCO26 simultaneous publication by Ryu et al: EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: A Randomized Placebo-Controlled Phase 2 Trial Read the full article: https://bit.ly/4uwIRQv

‼️ #ASCO26 simultaneous publication by Carlino et al: Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study Read the full article: https://ascopubs.org/doi/abs/10.1200/JCO-26-00835 #melsm

‼️ #ASCO26 simultaneous publication by Patel et al: Expert Validation of an Artificial Intelligence-Enabled Trial Matching Solution Using Real-World Data from Patients with Cancer Read the full article: https://bit.ly/4v854UY

‼️ #ASCO26 simultaneous publication by Bekaii-Saab et al: Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial Read the full article: https://bit.ly/3PF33Rd #gicsm

Great session happening now @ #ASCO26 in #JCO Central on leveraging AI to advance oncology publishing. Join us here at 11 AM (CT) for a session w/ #JCOGO editors discussing their special series "10 Years of the National Cancer Institute's Affordable Cancer Technology Program." https://bit.ly/4vgspE0

Happening now at #ASCO26 in #JCO Central (S402): “Pathways to Publication with the JCO Journals Editors-in-Chief.” A great opportunity to hear from them about how they got into the journals realm and ask questions in an intimate, laid-back setting. Stop by!

Happening now at #JCO Central (room S402) at #ASCO26: expert insight on translating science for practice from #ASCOEdBook Editor-in-Chief Dr. Gerald Hsu.

‼️ #ASCO26 simultaneous publication by Burtness et al: Amivantamab in Recurrent/Metastatic HNSCC after Checkpoint Inhibitor and Chemotherapy: Pivotal Results from the Phase 1b/2 OrigAMI-4 Study Read the full article: https://bit.ly/4vachDX #hncsm

‼️ #ASCO26 simultaneous publication by De Censi et al: Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis Read the full article: https://bit.ly/3PuKRK2 #bcsm

‼️ #ASCO26 simultaneous publication by Garrad et al: Artificial Intelligence in Hematology Oncology Fellowship Training: A Multicenter Survey of Education, Attitudes, and Clinical Use Read the full article: https://bit.ly/3PMitTx

‼️ #ASCO26 simultaneous publication by Chan et al: Structured Exercise Program Following Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial Read the full article: https://bit.ly/3RKAK4j #crcsm

‼️ #ASCO26 simultaneous publication by Dr. Andrea Necchi et al: Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial Read the full article: https://bit.ly/4nSZMdr #blcsm

‼️ #ASCO26 simultaneous publication by Dr. Nancy You et al: Impact of Dedicated Care Coordination on Access to Multidimensional Support Services in Young-Onset Colorectal Cancer: A Pragmatic Trial Read the full article: https://bit.ly/4u9XRmE #crcsm

#JCOGO EIC Dr. @kvanloonmd.bsky.social#JCOGOleads a session w panelists Drs Akhil Kapoor, Carlos Magliano & Celine Hoyek reviewing innovative approaches to evaluate alternative dosing or novel Tx strategies conducted in resource-constrained settings. Related #ASCOEdBook article: https://bit.ly/4wVoTAJ

Great conversations, bigger opportunities. 👥 Editorial Fellows Justin Barnes and Nicole Dalal hosted a roundtable discussion highlighting the collaborative, hands-on experience of the JCO OP Editorial Fellowship program.

“Our job as physicians is to notice, to listen, to observe. This is also what makes doctors great writers.” Happening now at #ASCO26, "The Art of Getting Published in the Art of Oncology" panel shares what editors look for: authenticity, humility, a strong arc, & a patient-first focus. ✍️🩺

‼️ #ASCO26 simultaneous publication by Trosman et al: Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancer Read the full article: https://bit.ly/4v6hwoa #lcsm #bcsm

"You aren't there to comment on the science, but to share the perspective of living with the disease." Great insights as JCO Fellow Tanmayi Pai leads our Clinical Trial Development panel on incorporating Patient-Reported Outcomes and working alongside patient advocates. #ASCO26 #ClinicalTrials

Happening now at #ASCO26, @ASCO and #JCO experts share insider tips on the ins & outs of medical publishing.

‼️ #ASCO26 simultaneous publication by Cathomas et al: Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19 Read the full article: https://bit.ly/4dLZUXz

‼️ #ASCO26 simultaneous publication by Wechalekar et al: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain (AL) Amyloidosis: Results from the Randomized CARES Trials Read the full article: https://bit.ly/43xGa5m

With 75% of cancer deaths in low-income countries due to high costs, JCO Global Oncology prioritizes affordable research to close the equity gap. Join #ASCO26 to discuss improving care: Saturday, May 30 4:45 – 6 PM (CT) Room S403 View the full schedule: https://bit.ly/4dQSanu

Have an impactful narrative but don’t know how to publish it? Join JCO Art of Oncology editors for “Publish in JCO’s Art of Oncology” at #ASCO26: Saturday, May 30 1:15 – 2 PM (CT) Room S402a, JCO Central Turn your stories into art. View the full schedule: https://bit.ly/4o4zkhd

High-impact research is a benchmark of success. Join JCO Journal editors for "The Ins and Outs of Medical Publishing" at #ASCO26: Friday, May 29 1 – 3:15 PM (CT) Room S103 Elevate your authorship skills and advance oncology. View the full schedule: https://bit.ly/4nGnIRf

‼️ #ctDNA26 simultaneous publication by Zhao et al: Beyond ctDNA for Efficacy: Can We Use cfDNA to Detect and Monitor Toxicity Signals? Read the full article here: https://bit.ly/4fw4dsB

⏰ Attending #ASCO26? Join #JCO Journals editors and editorial board members for one-on-one mentoring in JCO Central. Attendees interested in publishing may sign up for a 25-minute situational mentoring session. Sign-ups close tomorrow, May 21, at 11:59 PM (ET). Sign up today: https://bit.ly/4drDfzC

Recently published: 340B Drug Pricing Program: An Updated @ascocancer.bsky.social Policy Statement https://ascopubs.org/doi/10.1200/OP-26-00105

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology episode "The Liver We Share” by Ryan Wexler. After encountering a hepatectomy as a medical student, his journey comes full circle as he becomes a living liver donor for his wife: https://bit.ly/4cQ8e8f @mikkaelsekeres.bsky.social

Don’t miss out on the 10th Anniversary TAPUR Grand Rounds! Join the onc community May 12 for the Fourth Annual TAPUR Virtual Grand Rounds. As we celebrate 10 yrs of advancing precision medicine, this is your chance to hear directly from founding #TAPUR experts. Register today: https://bit.ly/485rXza